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Introduction
The role of surfactant in interstitial lung disease (ILD) has
drawn increasing attention in recent years, particularly with
the publication of the genetic determinants of surfactant
expression. This review will focus on surfactant abnormali-
ties in ILD, with emphasis on surfactant protein (SP) gene
polymorphisms.
Pulmonary surfactant is a mixture of phospholipids and
surfactant-specific proteins, which are essential for normal
lung function. The main function of pulmonary surfactant is
to stabilize the alveoli throughout the respiratory cycle,
preventing alveolar collapse at the end of expiration. Sur-
factant-specific proteins are also involved in host defense
and inflammatory processes in the lung.
Between 90% and 95% of lung surfactant is made up of
lipids, with the remainder being proteins. Roughly 65% of
the lipid component of surfactant is phosphatidylcholine.
The remaining 30–35% consists predominantly of phos-
phatidylglycerol, while phosphatidylinositol, phos-
phatidylethanolamine, phosphatidylserine and sphin-
gomyelin are also present in small amounts. The
surfactant-specific proteins are mainly composed of four
surfactant-associated proteins: SP-A, SP-B, SP-C and
SP-D, along with a minor component of mainly serum-
derived proteins. SP-A and SP-D are hydrophilic, while
SP-B and SP-C are highly hydrophobic proteins.
Surfactant phospholipids and SP-C are synthesized only
in the type II alveolar epithelial cells. The proteins SP-A,
SP-B and SP-D are produced by Clara cells and type II
alveolar epithelial cells in the lung. SP-A is the most abun-
dant surfactant protein and is completely lipid-bound. It is
a multimer containing the product of two genes: SP-A1
and SP-A2. SP-A and SP-D proteins are structurally
similar collagenous glycoproteins belonging to the col-
lectin superfamily. They are involved in host defense and
recognize the carbohydrate moiety on the surface of
pathogens. SP-B and SP-C are crucial in reducing surface
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tension by enhancing the adsorption and spreading of
phospholipid at the air–liquid interface. Absence of SP-B
production is lethal in infants and experimental animals [1].
Surfactant in interstitial lung disease
Several studies have explored the surfactant levels in
bronchoalveolar lavage (BAL) fluid in patients with ILDs.
More recently, serum levels of SPs have been studied and
correlated with disease progression.
Bronchoalveolar lavage studies
Idiopathic pulmonary fibrosis (IPF)
Early studies of surfactant in the bleomycin animal model of
lung injury showed significant alterations in the composition
and biophysical properties of surfactant. Studies of phos-
pholipid content of surfactant in BAL from IPF patients
showed significant abnormalities, including reduced alveolar
phospholipid, decreased content of phosphatidylglycerol
and a reduction in the phosphatidylglycerol/phosphotidyli-
nositol ratio [2]. Gunther et al. [3] studied the biophysical
properties of the surfactant obtained from normal control
subjects and IPF patients, and showed that the adsorption
and surface-tension-reducing properties were largely lost in
virtually all patients with IPF.
McCormack and colleagues [4] hypothesized that the
alteration in the surfactant lipid composition changes its
biophysical activity, diminishes lung compliance and pro-
motes lung fibrosis. Since SP-A plays an important role in
the surface-tension-lowering abilities of surfactant, they
measured the SP-A levels in BAL fluid. In addition to
reduction in phospholipid content, SP-A levels were also
significantly reduced in patients with IPF. The SP-A/phos-
pholipid ratio correlated with disease course over a six-
month period and with mortality. In a follow-up study,
surfactant levels in BAL fluid were correlated with survival.
The mean SP-A/phospholipid ratio was lower in patients
with IPF than in healthy volunteers, and the magnitude of
reduction was predictive of survival in patients at two
years [4]. Others have found a similar reduction in the SP-
A levels in patients with IPF but no change in SP-B or SP-
D levels [1,3]. Levels of SP-C in BAL fluid of IPF patients
are not known. It is clear that there are alterations to the
biochemical composition of surfactant in IPF. It is possible
that these alterations play an important role in the progres-
sion of the disease. Whether the immunological properties
of the SPs play a role in the development of the disease
needs to be studied.
Other interstitial lung diseases
In sarcoidosis, no substantial changes in surfactant phos-
pholipid profile have been reported in several studies [3].
However, conflicting results have been reported regarding
SP-A levels. While van de Graaf et al. found unchanged
levels of SP-A [5], others have found increased [6] or
decreased levels [3]. Although it is possible that the
abnormalities may reflect different clinical stages of the
disease, it is thought, in general, that sarcoidosis is not
associated with major pulmonary surfactant abnormalities
[1]. In hypersensitivity pneumonitis, moderate changes in
phospholipid profile with reduction in phosphatidylglycerol
have been noted [3]. While elevated SP-A levels have
been reported in acute disease [7], both low and high
levels have been reported in other studies [3,6]. Pul-
monary alveolar proteinosis is characterized by the abun-
dance of periodic acid Schiff (PAS) material, which fills
the alveolar spaces. In the adult form of the disease, the
material is composed of glycoprotein and lipids. SPs A, B,
C, and D are all increased in BAL fluid. While the phos-
pholipids have been found to be normal, structural alter-
ations in SP-A and SP-B have been described [8,9].
Serum studies
Recently, Takahashi and colleagues reported the serum
levels of SP-A and SP-D, and disease extent in IPF and
lung fibrosis associated with scleroderma [10]. In IPF,
both SP-A and SP-D concentrations correlated signifi-
cantly with the extent of alveolitis but not progression of
fibrosis. As opposed to lower BAL fluid SP-A levels pre-
dicting poor prognosis in other studies, they found that the
serum levels were higher in patients who died within three
years when compared with patients who lived longer. In
scleroderma, the serum levels of SP-A and SP-D were
higher in patients with ILD (based on computerized
tomography) when compared with patients without any
interstitial disease [10,11].
In summary, both lipid and protein components of surfac-
tant can be abnormal in most ILDs, particularly IPF, and
there is evidence to suggest that SP abnormalities may be
related to survival in specific diseases. Are these changes
genetic or do they merely reflect prior tissue damage? An
understanding of the genetics of the underlying lung
disease in general, and SP expression in particular, may
be important in defining susceptibility to and progression
of these conditions.
Genetics of interstitial lung disease
The development of ILDs is thought to occur in genetically
susceptible individuals, following exposure to a variety of
potential environmental triggers. Support for a genetic
influence in the development of ILDs comes from two
types of observation. First, there is variable susceptibility
to environmental causes, and second, familial disease has
been reported in most ILDs, including sarcoidosis, IPF,
alveolar proteinosis, Langerhans cell histiocytosis, hyper-
sensitivity pneumonitis and desquamative interstitial pneu-
monia (see Supplementary Table 1).
Complex diseases
ILDs are relatively rare and susceptibility does not follow
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genetically as ‘complex diseases’. Variations at multiple
loci, each exerting variable and relatively small effects, are
likely to be involved. Further complications in assigning
susceptibility involve the assessment of interactions with
environmental factors that are thought to induce a specific
clinical phenotype, and the knowledge that interactions
between genes and the environment can affect the rela-
tionships of severity and progression as well as predispo-
sition to disease. Finally, some conditions, such as IPF,
manifest in the later stages of life, making family-associa-
tion studies difficult. For these reasons, most studies of
the genetics of ILDs have applied the direct case-con-
trolled, association-based approach. In such studies, the
prevalence of alleles in single-nucleotide polymorphisms
(SNPs) in biologically important candidate genes is exam-
ined in populations of unrelated affected individuals, and
compared with prevalence in unrelated normal controls.
Genetic studies in interstitial lung disease
Very few studies have examined the genetic components
predisposing to ILDs and, of these, most have focused on
the region of chromosome 6, which incorporates the major
histocompatibility complex (MHC) and its associated
genes. The consensus from the majority of the studies is
that susceptibility to sarcoidosis is associated with
HLA-DRB1*03, *11, *12, *13, *14. Other associations
include alleles in the genes encoding TAP2, the CC
chemokine receptor 2, the angiotensin-converting enzyme
and vitamin D receptor [12]. Polymorphisms in the
fibronectin gene [13] and the HLA-DPB1*1301 allele [14]
have been associated with fibrosing alveolitis in the
context of systemic sclerosis. Susceptibility to IPF has not
been associated with polymorphisms in TNFα, LTα, TNF
receptor II and IL-6 genes [15], nor with polymorphisms in
the IL-8 and IL-8 receptor (CXCR-1 and CXCR-2) genes
[16]. A reported association with the IL-1 receptor-antago-
nist gene [17] was not confirmed in a subsequent study.
Polymorphisms in the surfactant genes
The genes for the hydrophilic proteins SP-A1, SP-A2 and
SP-D have been mapped to human chromosome 10q22-
q23.1. The SP-A1 gene is telomeric to the SP-A2 and SP-
D genes: the SP-A2 and SP-D genes are located 36 kb
and 130 kb respectively from SP-A1. Both SP-A1 and SP-
A2 genes have a number of 5′-untranslated region exons
that splice under genetic control in different configurations
to produce a number of alternatively spliced functional
variants [18]. Furthermore, there are a number of polymor-
phisms within the coding region of the genes that result in
amino acid substitutions [19]. In the SP-A1 gene there are
five exonic polymorphisms, which correspond to amino
acid (aa) positions 19, 50, 62, 133 and 219 of the protein.
Two of these are silent (62 and 133), while the others
result in a non-conservative amino acid substitution
(Ala19→Val, Leu50→Val and Arg219→Trp). In the SP-A2
gene, there are four exonic polymorphisms (Thr9→Asn,
Pro91→Ala and Lys223→Gln); the polymorphism at posi-
tion 140 is silent. Nineteen haplotypes have been identi-
fied in the SP-A1 gene (designated 6A to 6A20), and 15
haplotypes have been identified in the SP-A2 gene (desig-
nated 1A to 1A13) [19]. Of these haplotypes, the most fre-
quent are the SP-A1 (6A2) and SP-A2 (1A0) haplotypes.
These two haplotypes comprise the following amino acids:
SP-A1 (6A2: Val19/Val50/Arg219) and SP-A2 (1A0:
Asn9/Ala91/Gln223). In functional studies, these haplo-
types correlated with low or moderate mRNA levels [18].
In the SP-D gene there are two exonic polymorphisms that
result in substitutions: Thr11→Met and Thr160→Ala [19].
Genes mapped to human chromosomes 2p12-p11.2 and
8p21 encode the hydrophobic proteins SP-B and SP-C
respectively. Several SNPs have been identified in the SP-
B gene. Four of these polymorphisms, which reside in the
5′ flanking region, intron 2, exon 4 and 3′ untranslated
regions of the gene, have the potential to affect function
[20]. The exonic polymorphism substitutes residue 131
(Thr→Ile). There is also a variable nucleotide tandem
repeat region , which is highly polymorphic, within intron 4
of the SP-B gene [21]. For the SP-C gene, there may be
several SNPs as there are a number of variations between
published SP-C sequences [22]. Figure 1 shows the
intron/exon structure of the SP genes with the locations of
polymorphisms discussed above.
Mutations in the surfactant genes
A locus is considered polymorphic if the less frequent
allele has a population frequency of at least 1% and
heterozygosity frequency of at least 2%. Below these fre-
quencies, nucleotide variations are allelic variants or, if
very rare, they are described as mutations [23]. A number
of mutations have been identified in association with
hereditary surfactant deficiencies. The predominant, but
not exclusive, mutation responsible for SP-B deficiency
involves a substitution of a GAA nucleotide triplet for a
single C in codon 121, which causes a frameshift and a
premature termination signal and also interferes with SP-C
processing [24]. Mutations in the SP-B gene are also
responsible for SP-B deficiency in congenital alveolar pro-
teinosis [25]. Until the recent work published by Nogee et
al. [26], there were no data on SP-C mutations and lung
disease.
SP-C gene variations in ILD
Nogee  et al. [26] recently reported an association
between a mutation in the SP-C gene and ILD. A full-term
baby was born to a woman with a history of desquamative
interstitial pneumonia, which was diagnosed when she
was one year old and had been treated with corticos-
teroids up to the age of 15. The baby was normal at birth
but developed respiratory symptoms at six weeks of age.
Lung biopsy revealed cellular, or non-specific, interstitial
pneumonia. The infant improved with oxygen and cortico-
Available online http://respiratory-research.com/content/3/1/14steroid therapy. The mother’s lung disease worsened and
she died of respiratory failure.
Genetic analysis showed a mutation in one allele of the
SP-C gene. The heterozygous substitution of A to G was
located in the first base of intron 4, abolishing the normal
donor splice site and resulting in the skipping of exon 4
and the deletion of 37 amino acid residues in the SP-C
precursor protein. Abnormal protein structure is known to
result in abnormal tertiary structure and transport. Mature
SP-C was completely absent from the BAL fluid and lung
tissue of the patient and might have resulted from this
aberrant folding and transport. The complete absence of
protein with the mutation of a single allele is possibly due
to a dominant–negative effect, in which the mutant allele
suppresses production of the normal allele [26].
The authors subsequently studied the SP-C gene in 34
infants with nonfamilial chronic lung disease of unknown
origin (Nogee et al., personal communication, 2001). They
were able to identify mutations of the SP-C gene in 11
infants, which resulted in a phenotype similar to that of the
index patient. The occurrence of a de novo mutation that
is functionally identical to a familial mutation strongly sup-
ports the hypothesis that the mutations were causally
related to the lung disease. This suggests that SP-C is
necessary for normal lung function in the postnatal period.
Surfactant SNP disease-association studies
No other studies have examined surfactant-gene polymor-
phisms in the context of ILDs, although these have been
evaluated in other pulmonary conditions. In a recent publi-
cation [27], the SP-B Thr131→Ile polymorphism was
found to be associated with the acute respiratory distress
syndrome. Alleles in the SP-B variable nucleotide tandem
repeat region and SP-A polymorphisms have been
reported to be associated with the infant respiratory dis-
tress syndrome [21,28], but more recent data suggest
that genetic susceptibility to infant respiratory distress
syndrome is dependent on SP-A alleles in the context of
SP-B Thr131 homozygosity [29]. The SP-A1 polymor-
phism 6A6 is also over-represented in infants with bron-
chopulmonary dysplasia [30].
Conclusion
In summary, genetic variations are factors in determining
the development and severity of many ILDs. Surfactant
plays an important role in lung physiology and defense,
and surfactant gene variations have been associated with
several lung diseases. The recent finding of surfactant
gene variations in familial and nonfamilial ILD opens up a
new area for more detailed analysis, to explore whether
these variations play a role in a wider range of ILDs.
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Supplementary Table 1
Studies of genetic polymorphisms in various interstitial lung diseases
Disease Associated gene products References
Idiopathic pulmonary fibrosis (IPF) HLA [S1]
IL-1, TNF-alpha [15,17,S2]
Chemokines [16]
ACE [S3]
Sarcoidosis HLA [S4–S21]
ACE [S22–S29]
TNF-alpha [S30–S34]
Chemokines [S35,S36]
NRAMP [S37]
Mannose-binding lectin [S38]
Vitamin-D receptor [S39,S40]
IL-1 [S41]
Fibrosing alveolitis in scleroderma Fibronectin [13]
HLA [14]
Extrinsic allergic alveolitis TNF-alpha [S42]
Langerhan’s cell histiocytosis TNF-alpha [S43]
ACE, angiotensin-converting enzyme; IL-1, interleukin-1; NRAMP, natural resistance-associated macrophage protein; TNF, tumor necrosis factor.S19. Lympany PA, Petrek M, Southcott AM, Newman Taylor AJ,
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